Massive study digs into genetic roots of stomach cancer
NCT ID NCT03030404
First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 12 times
Summary
This study collected information from 733 people with a personal or family history of hereditary stomach cancer. The goal was to better understand how these cancers develop and what genes are involved. Participants provided medical history, blood samples, and genetic testing. The study did not test a new treatment, but aimed to improve knowledge for future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
733 people
The number who actually took part.
- Started
-
Jan 2017
- Finished
-
Mar 2025
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals, and family members, who fulfill clinical criteria for a hereditary gastric cancer syndrome irrespective of previous genetic testing or treatment
- Ages
-
2 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
-INCLUSION CRITERIA: 1. An individual, or their family members, with any of the following: * Fulfills clinical criteria for Hereditary Diffuse Gastric Cancer (HGDC) syndrome or Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) syndrome. * Clinically suspicious personal or family medical history of gastric cancer or gastric cancer syndrome that warrants genetics evaluation. * Current diagnosis of gastric cancer and a germline mutation associated with a known cancer syndrome or an associated family history of gastric cancer. * Harbors a pathogenic germline mutation known to predispose to gastric cancer. * First-degree relatives, regardless of family history or personal history of cancer, with a documented deleterious germline mutation (including but not limited to CDH1, CTNNA1, SDH) known to predispose to gastric tumors. * Diagnosis or suspicion of a premalignant or malignant stomach lesion of suspected hereditary etiology. 2. Age \>= 2 years and older. Note: Patients under 18 years of age may only participate in research sample collection if the tissue acquisition is performed during a clinically indicated surgical procedure, and the sampling of tissue, blood, saliva or urine collection does not add risk to the clinically indicated procedures. 3. Ability of subject or legally authorized representative (LAR) to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: None.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Familial diffuse gastric cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a Chemo-Immunotherapy cocktail extend life in advanced stomach cancer?
- AI reads tumor slides to match cancer patients with trials
- Can a targeted therapy tame hard-to-treat stomach and esophageal cancers?
- Can a Two-Drug combo beat single painkiller after stomach surgery?
- Can a modified stomach bypass speed up recovery in advanced gastric cancer?